- €13.00bn
- €12.43bn
- €3.93bn
Brief: Ipsen Shares First Aesthetic Data For IPN10200 In Phase II Trial
Brief: Bylvay (Odevixibat) Approved In Japan For Rare Liver Disease Pfic
Brief: Ipsen Now Expects 2025 Sales Growth Above 7%
Brief: Ipsen SA Says Cabometyx Approved In EU For Previously Treated Advanced Neuroendocrine Tumors
Brief: Ipsen Initiates Share Buy-Back Program
Brief: Ipsen SA Says Late-Breaking Analysis Demonstrates Characteristics Associated With Long-Term Overall Survival With Onivyde Regimen In Metastatic Pancreatic Adenocarcinoma
Brief: Ipsen: Impact Of Iqirvo On Fatigue
Health Rounds: Exposure to bacterial toxin may explain earlier age colon cancer rise
Brief: Ipsen: Elafibranor Shows Favorable Safety Profile And Efficacy In PSC
Europe Research Roundup: Airbus, Deutsche Telekom, L'Oreal
Brief: Ipsen Q1 Revenue At EUR 918.8 Mln
Europe Research Roundup: Adidas, AXA, Greencore
Brief: Ipsen Issues EUR 500 Mln Inaugural Rated Public Bond
Ipsen falls after 'lower-quality' beat on Q4 sales, 2025 guidance
Brief: Ipsen FY 2024 Total Sales Growth Of 9.9% At Cer, 8.7% Reported
Brief: Ipsen FY Adjusted EPS EUR 10.27 Vs. IBES Estimate EUR 9.5
Crinetics gains after TD Cowen starts with 'buy' on optimism for lead drugs
Former exec at drugmaker Ipsen sentenced to prison for insider trading (updated)
Former exec at drugmaker Ipsen sentenced to prison for insider trading